


## PHARMACEUTICAL 2019



## Y-mAbs Therapeutics Inc. Rank 96 of 371





## PHARMACEUTICAL 2019



## Y-mAbs Therapeutics Inc. Rank 96 of 371

The relative strengths and weaknesses of Y-mAbs Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Y-mAbs Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 373% points. The greatest weakness of Y-mAbs Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is -25%, being 306% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	151,532
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,123
Liabilities, Non-Current	224
Other Assets	187
Other Compr. Net Income	175
Other Expenses	0
Other Liabilities	2,050
Other Net Income	-44
Property and Equipment	205
Research and Development	34,269
Revenues	0
Selling, General and Administrative Expense	8,961

Output Variable	Value in 1000 USD
Assets	151,924
Liabilities	11,397
Expenses	43,230
Stockholders Equity	140,527
Net Income	-43,274
Comprehensive Net Income	-43,186
Economic Capital Ratio	-25%